VivoSeq
Other

Gastric Acid

0

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Gastric Acid is an early-stage landscape with 0 programs across 3 companies. The most active players are Takeda, Bristol-Myers Squibb, AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

71/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

14

clinical trials

Completed10 · 71%
Withdrawn3 · 21%
Terminated1 · 7%

Clinical Trials

Trial Activity

14 trials

The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects
Completed·TTufts University·N/A·NCT00336739·17 enrolled
Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients
Completed·UUniversity of Kansas Medical Center·Phase 2·NCT00222131·73 enrolled
The Effect of Protein on Calcium Absorption and Gastric Acid Production
Completed·YYale University·Phase 4·NCT00719160·12 enrolled
Effects of Gastric Acid on Colonic Microbiome
Completed·—·Phase 4·NCT01901276·14 enrolled
Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression
Completed·—·Phase 4·NCT00903448·40 enrolled
The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00001191
A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT03979248·21 enrolled
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT04564040·20 enrolled
Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression
Completed·—·Phase 4·NCT00808769·30 enrolled
A New Method for Determining Gastric Acid Output Using a Wireless Capsule
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00702533·80 enrolled
Comparison of the Gastric Acid Suppressive Effects of Esomeprazole and Generic Omeprazole
Terminated·QQueen's University·Phase 3·NCT00542347·20 enrolled
CYP2C19 Genotype Predictor of Gastric Acid Suppression
Withdrawn·MMayo Clinic·Phase 1·NCT01824199
Magnesium Pantoprazole 20mg b.i.d. vs Magnesium Pantoprazole 40mg q.d. on Intragastric Acid Inhibition
Withdrawn·Takeda logoTakeda·Phase 3·NCT01499693
Gastric Acid Rebound Secretion Measured by Alkaline Tide
Withdrawn·RRabin Medical Center·Phase 1·NCT01315444

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)